Lenvatinib (E7080; Lenvima ®) is an oral ATP-competitive MKI with activity against FLT-1, FLT-4, KIT, FGFR1, PDGFR, VEGFR1-3, and can inhibit angiogenesis and growth of SCLC and breast cancer cells in vitro and in vivo (208–211). The gene discussed is FLT1; the disease is small cell lung carcinoma.